The effect of vitamin A, B, C, D, and E supplementations in COVID-19

The effect of vitamin A, B, C, D, and E supplementations on biochemical parameters of critically ill patients with COVID-19: A randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151226025699N5

Enrollment

135

Registered

2021-04-07

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: The intervention group in addition to receiving routine ICU medications according to the national protocol, which includes hydroxychloroquine sulfate, chloroquine phosphate, kaletra (l

Eligibility

Sex/Gender

All

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Written consent for participation Age over 34 years A diagnosis of COVID-19 based on symptoms such as severe pneumonia, fever, fatigue, dry cough, respiratory distress, and lungs involvement in the computed tomographic (CT) scan according to the doctor's confirmation Awareness score of at least 3 based on the 15-point Glasgow Coma Score (GCS)

Exclusion criteria

Exclusion criteria: Not tendency to participate in the study Diagnosed cardiovascular and lung diseases which can disturb the study process A diagnosis of malignant tumors Recent use of chemotherapy drugs Having incomplete medical records Non-compliance with the vitamin A, B, C, D, and E supplementations Consumption of vitamin A, B, C, D, and E supplementations during the last 3-month before the study Pregnancy in women

Design outcomes

Primary

Measure	Time frame
White blood cells (WBCs). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Neutrophils. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lymphocytes. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lactate dehydrogenase (LDH). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Creatine phosphokinase (CPK). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Cell blood count (CBC). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;C reactive protein. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Partial pressure of oxygen (PO2). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Partial pressure of carbon dioxide. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.	—

Measure

Time frame

White blood cells (WBCs). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Neutrophils. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lymphocytes. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lactate dehydrogenase (LDH). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Creatine phosphokinase (CPK). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Cell blood count (CBC). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;C reactive protein. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Partial pressure of oxygen (PO2). Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Partial pressure of carbon dioxide. Timepoint: Baseline, 20-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Moslem

Sabzevar University of Medical Sciences

alirezamoslem@gmail.com+98 51 4401 1004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026